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IRAK1 is involved in the regulation of type I IFN production downstream of TLR3. Previous work indicated that IRAK1 negatively
regulates TRIF-mediated activation of IRF3 and IRF7. We report that IRAK1 limits the activation of the TLR3–NF-kB pathway.
Following TLR3 stimulation, IRAK1-deficient macrophages produced increased levels of IL-6 and IFN-b compared with wild type
macrophages. Pharmacological inhibition of TAK1 reduced this increase in IFN-b, together with the heightened activation of
IRF3 and p65 found in TLR3-ligand stimulated IRAK1-deficient macrophages. Recently, IKK« and TANK-binding kinase 1
(TBK1) were reported to limit activation of the NF-kB pathway downstream of IL-1R, TNFR1, and TLRs. We show that TBK1
has a positive role in the TLR3–NF-kB pathway, because we detected reduced levels of IL-6 and reduced activation of p65 in
TBK1-deficient macrophages. In contrast, we show that IKK« limits the activation of the TLR3–NF-kB pathway. Furthermore,
we show that IRAK1 is required for the activation of IKK« downstream of TLR3. We report impaired activation of ERK1/2 in
IRAK1– and IKK«-deficient macrophages, a novel finding for both kinases. Importantly, this work provides novel mechanistic
insight into the regulation of the TLR3-signaling pathway, providing strong evidence that an IRAK1-IKK«–signaling axis acts to
limit the production of both type I IFNs and proinflammatory cytokines by regulating TAK1 activity. The Journal of Immunol-
ogy, 2013, 190: 2844–2856.
I
nterleukin-1 receptor associated kinase (IRAK)-1 is a serine/
threonine kinase that was previously shown to be essential for
IFN-a production downstream of TLR-7 and TLR-9 sig-
naling in plasmacytoid dendritic cells (1). In contrast, in TIR
domain-containing adaptor inducing IFN-b (TRIF)-dependent
signaling, IRAK1 has been proposed to act as a negative regulator
of type I IFN production, negatively regulating the activation of
IRF3 and IRF7 (2).
TLR-3–mediated activation of NF-kB and IRF3 is thought to
bifurcate at the level of TRIF (3). The N terminus of TRIF in-
teracts with TNFR-associated factor (TRAF)6 and TRAF family
member–associated NF-kB activator (TANK)-binding kinase
(TBK)1 (4), whereas the C terminus of TRIF binds receptor-
interacting protein (RIP)1 (5). TRAF6 and RIP1 have both been
implicated in NF-kB activation downstream of TLR3, and re-
cruitment of RIP1, TRAF6, and transforming growth factor-
b-activated kinase 1 (TAK1) to the receptor following ligand
stimulation has been demonstrated (6). In TLR3 signaling, TAK1
has an essential role in NF-kB activation, because TAK1-deficient
cells fail to activate NF-kB (7). TRAF6-mediated K63-linked
polyubiquitination was proposed to be required for TAK1 acti-
vation (8). Phosphorylation at key residues located in the activa-
tion loop of IkB kinase (IKK)a (S176/180) and IKKb (S177/181)
is required for their activation, and TAK1 was shown to phos-
phorylate IKKb in the activation loop (9). IKKa and IKKb were
found to phosphorylate the NF-kB inhibitor IkB (10, 11), which
targets IkB for degradative polyubiquitylation, allowing for NF-
kB nuclear translocation. Phosphorylation of RelA/p65 at several
serine residues, including those in the transactivation domain, is
required for optimal NF-kB activity, and several kinases have
been implicated, including IKKa/b, TBK1, and IKKε (12–14). In
TLR signaling, TAK1 is involved in the activation of the MAPKs
JNK, p38, and ERK1/2 (9, 15).
Both TBK1 and IKKε can directly phosphorylate IRF3 at key
serine residues in the C terminus of IRF3, leading to its homo-
dimerization and nuclear translocation. Studies of IKKε- and
TBK1-knockout mice confirmed a critical role for TBK1 in the
induction of type I IFNs in response to viral infection, whereas
IKKε deficiency had no significant impact on type I IFN pro-
duction (16, 17). The coordinate assembly of a number of tran-
scription factors on the IFN-b enhancer is required for the efficient
transcriptional regulation of the IFN-b gene. The IFN-b enhancer
contains four overlapping positive regulatory domains (PRDs)
designated PRDII, PRDIII-I, and PRIV, which bind NF-kB, IRF3/7
and ATF-2/c-Jun heterodimer, respectively. IRF3 and/or IRF7
have essential roles in the production of IFN-b and other type I
IFNs following viral infection. NF-kB and AP-1 have critical roles
in maintaining constitutive IFN-b expression, which primes cells
to a viral-ready state, and a less important role in IFN-b pro-
duction following viral infection (18, 19).
Recently, IKKa and IKKb were reported to phosphorylate and
activate the noncanonical kinases, TBK1 and IKKε, in TNF and
TLR signaling (20). A second pathway coexists in IL-1R, TLR3,
and TLR4 signaling that culminates in the autocatalytic activity of
TBK1 and IKKε (20). TBK1 and IKKε were reported to activate
a negative-feedback loop that limits the activation of NF-kB, and
IKKa, IKKb, and NEMO were identified as potential targets (20).
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We present novel findings implicating IRAK1 and IKKε as key




HEK293 cells stably expressing TLR3 (TLR3 HEK293) were purchased
from InvivoGen. Parental HEK293 (wild type [WT]) and IRAK1-deficient
HEK293I1A cells were provided by Dr. Xiaoxia Li (Cleveland Clinic
Foundation, Cleveland, OH). WT, IRAK12/2, IKKε2/2, TBK1+/+
TNFR12/2, and TBK12/2 TNFR12/2 bone marrow–derived macrophages
(BMDMs) were gifts from Dr. Kate Fitzgerald (University of Massachu-
setts Medical School, Worcester, MA). The human microglial cell line
CHME3 was provided by Dr. M. Naghavi (Columbia University, New
York, NY).
Plasmids
Constructs encoding WT and kinase-dead IRAK1 (IRAK1 D340N) were
from Tularik (San Francisco, CA). The pRL-TK plasmid encoding for
Renilla luciferase was purchased from Promega, and pcDNA3.1 was from
Invitrogen. Constructs encoding TBK1-flag, IKKε-flag, IFN-b, PRDII, and
PRDIII-I luciferase reporters were provided by Dr. Kate Fitzgerald. IRF3
activation was assessed using pFR-Luc and the trans-activator plasmid
pFA-IRF3 (IRF3 fused downstream of the yeast Gal4 DNA binding do-
main; provided by Dr. Kate Fitzgerald). The Gal4-p65(1–551) construct
encoding for full-length p65 fused to the Gal4 DNA-binding domain was
a gift from Dr. Lienhard Schmitz (German Cancer Research Center, Hei-
delberg, Germany).
Abs and reagents
Anti–phospho-IKKa/b clone 16A6, anti–phospho–NF-kB p65 (Ser536)
clone 93H1, anti–NF-kB p65 clone 93H1, anti–phospho-TBK1/NAK
(Ser172) clone D52C2, anti–phospho-IRF3 (Ser396) clone 4D4G, anti-
IRF3 clone D83B9, anti-IKKε clone D61F9, anti–phospho-p44/42
MAPK (Erk1/2; Thr202/Tyr204) clone D13.14.4E, anti-p44/42 MAPK
(Erk1/2) clone 137F5, anti–phospho-SAPK/JNK (Thr183/Tyr185) clone
81E11, anti-SAPK/JNK clone 56G8, anti–phospho-p38 MAPK (Thr180/
Tyr182) clone D3F9, anti-p38 MAPK, anti–phospho-TAK1 (Thr184/187)
clone 90C7, and anti-TAK1 clone D94D7 were all from Cell Signaling
Technologies. Other Abs used were anti- IRAK1 clone H-273 and anti-
TBK1 clone 6D603 (both from Santa Cruz); anti–b-actin clone AC-15,
anti-Flag clone M2, and anti-c-Myc clone 9E10 (Sigma-Aldrich), and anti-
TBK1 (pS172) clone J133-1171 (BD Pharmingen). Polyinosinic-
polycytidylic acid [poly(I:C)] (high m.w.) was purchased from Invivo-
Gen. IRAK1/4 inhibitor and the TAK1 inhibitor, (5Z)-7-oxozeaenol, were
both purchased from Merck (Darmstadt, Germany). The IKKε and TBK1
inhibitor MRT67307 was obtained from the Medical Research Council Pro-
tein Phosphorylation Unit, University of Dundee (Dundee, Scotland, U.K.).
Reporter gene assays
TLR3-HEK293 cells or HEK293-I1Awere seeded onto 96-well plates and
grown for 24 h. Cells were then transfected using GeneJuice Transfection
Reagent (Novagen) with expression constructs and luciferase reporter
genes. Twenty-four hours posttransfection, cells were left untreated or were
stimulated with poly(I:C) for 6 h, harvested in reporter lysis buffer
(Promega), and assayed for firefly and Renilla luciferase activity using the
luciferase assay system and coelenterazine (Promega). Each experiment
was performed in triplicates; the mean fold induction (6 SEM) relative to
control levels was calculated in at least three independent experiments.
RNA interference/small interfering RNA gene silencing
Predesigned small interfering RNA (siRNA) targeting IRAK1 (sense: 59-
GGUUGUCCUUGAGUAAUAATT-39; antisense: 59-UUAUUACUCAA-
GGACAACCTG-39), A20 (sense: 59-AGUGUGUAUCGGUGCAUGG-
UU-39; antisense: 59-CCAUGCACCGAUACACACUUU-39), and Lamin
A/C (sense: 59-GAAGGAGGGUGACCUGAUATT-39; antisense: 59-UA-
UCAGGUCACCCUCCUUCTT-39) were purchased from Ambion. siR-
NAs targeting IKKε (IKKε siRNA 1 sense: 59-GCGGAACAAGGAGA-
UCAUTT-39; IKKε siRNA 1 antisense: 59-AUGAUCUCCUUGUUCC-
GCCGT-39; IKKε siRNA 2 sense: 59-AGAUGAACUUCAUCUACAATT-
39; IKKε siRNA 2 antisense 59-UUGUAGAUGAAGUUCAUCUTG-39)
were purchased from QIAGEN. Twenty-four hours later, TLR3-HEK293
cells were transfected with the specific siRNA oligonucleotides or negative
control siRNA (IRAK1 or A20 at 15 nM final concentration; IKKε at 30
nM final concentration) using Lipofectamine RNAiMAX Transfection
Reagent (Life Technologies). The transfected cells were incubated for 35–
40 h for IRAK1 and A20 experiments or $48 h for IKKε before DNA
transfection. DNA was transfected using GeneJuice Transfection Reagent
(Novagen), as described previously. Cells were treated with poly(I:C) for 6
h and then harvested and subjected to reporter gene assay. Knockdown was
confirmed by Western blotting.
ELISA
Murine and human IL-6 ELISA Development Kits were purchased from
PeproTech. Mouse IFN-b ELISA was obtained from R&D Systems. The
cytokine levels were determined according to the manufacturers’ instruc-
tions. Each experiment was performed in triplicates, and the average (6
SEM) was calculated for at least three independent experiments
Real-time PCR
Total RNA was extracted from cell cultures using TRIzol Reagent (Invi-
trogen). First-strand cDNA synthesis was carried out according to the
manufacturer’s instructions using Moloney murine leukemia virus reverse-
transcriptase RNase H minus (Metabion International, Martinsried, Ger-
many). Quantitative real-time PCR was performed on a real-time PCR
system (DNA Engine OPTICON system; MJ Research) using Maxima
SYBR Green qPCR Master Mix (Thermo Scientific). The data were ana-
lyzed using the 22DDCT method (21), with all samples normalized to
GAPDH. All experiments were performed in triplicate.
Kinase assay
A total of 50 ng N-terminal 6xHis-tagged, recombinant human active
IRAK1 (Millipore) was diluted in kinase buffer (40 mM HEPES [pH 7.4],
40 mM MgCl2, 4 mM DTT, 0.1 mM EGTA) and preincubated with 1 mM
the IRAK1/4 inhibitor or an equal volume of DMSO for 15 min at room
temperature. The tubes were incubated for 30 min at 30˚C in the presence
of 20 mM cold ATP, boiled, and subjected to immunoblotting.
Western blot analysis and immunoprecipitation
HEK293 or HEK293I1A cells were seeded and transfected at ∼80%
confluency using GeneJuice. Transfected cells were incubated at 37˚C for
24 h. Cells were then lysed in lysis buffer containing 50 mM Tris-HCl [pH
7.5], 150 mM sodium chloride, 0.5% (v/v) IGEPAL, 50 mM sodium
fluoride, 1 mM sodium orthovanadate, 1 mM DTT, 1 mM PMSF, protease
inhibitor mixture. The lysates were resolved by SDS-PAGE, transferred to
nitrocellulose membranes (Whatman), and probed with the indicated Abs.
BMDMs were seeded in 10-cm dishes, treated 24 h later with poly(I:C) for
the indicated times, and harvested in lysis buffer. The indicated Abs were
precoupled with Agarose A/G beads (Santa Cruz) overnight at 4˚C and
then cell lysates were added to the mix overnight. The resulting immune
complexes were analyzed by SDS-PAGE and immunoblotting using the
indicated Abs.
Statistical analysis
Data analysis was carried out using the unpaired Student t test: *p , 0.05,
**p , 0.01, ***p , 0.001.
Results
IRAK1 regulates IFN-b and proinflammatory cytokine
production downstream of TLR3
HEK293 cells stably expressing TLR3 were transiently transfected
with the IFN-b luciferase (Fig. 1A), PRDIII-I luciferase (Fig. 1B),
and PRDII luciferase (Fig. 1C) reporter plasmids in the presence
of empty vector (EV), IRAK1, or kinase-inactive IRAK1 (IRAK1
KD; IRAK1 D340N) expression constructs. The cells were then
stimulated with poly(I:C) for 6 h, and the luciferase activities were
measured. IRAK1 inhibited poly(I:C)-induced activation of the
IFN-b, PRDIII-I, and PRDII reporters compared with control EV-
transfected cells (Fig. 1A–C). This inhibition was dependent on
the kinase activity of IRAK1, because kinase–inactive IRAK1
failed to inhibit poly(I:C)-induced activation of these same re-
porters (Fig. 1A–C). Next, we knocked down the expression of
IRAK1 in TLR3-expressing HEK293 cells through siRNA (Fig.
1D–F, Supplemental Fig. 1A–D). As a control, we silenced the
expression of A20, a recognized negative regulator of TLR3 sig-
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FIGURE 1. IRAK1 regulates poly(I:C)-induced IFN-b and IL-6 production. TLR3 HEK293 cells were transiently cotransfected with IFN-b promoter
(80 ng; A), PRDIII-I (120 ng; B), or PRDII (80 ng; C) reporter constructs, together with EV pcDNA3.1, IRAK1, and IRAK1 KD expression plasmids (100
ng), as indicated. TK Renilla (20 ng) was cotransfected as an internal control. Twenty-four hours after transfection, cells were left untreated or were
stimulated with poly(I:C) for 6 h and then harvested. Reporter gene activities were measured, and the values were normalized for transfection efficiency
through Renilla luciferase expression. Data are presented as fold stimulation of luciferase expression relative to unstimulated cells. Data are the mean 6
SEM (n = 3). (D–F) A total of 15 nM of siRNA against lamin A/C, IRAK1, or A20 was transfected in TLR3-HEK293 cells using Lipofectamine. After a
30-h incubation, the cells were cotransfected with the indicated reporter constructs, as detailed above. After 24 h, the cells were stimulated with poly(I:C)
for 6 h, and the reporter gene activities were measured and normalized through Renilla luciferase expression. Data are the mean 6 SEM (n = 3). WT or
IRAK12/2 BMDMs were stimulated with 50 mg/ml poly(I:C) (G, J) or LPS (1 mg/ml) (H). Supernatants were collected at 8 and 24 h poststimulation, and
IFN-b and IL-6 levels were measured by ELISA. (I and K) WT BMDMs were pretreated for 1 h with 1 mM IRAK1/4 inhibitor or an equal amount of
DMSO and then stimulated with 50 mg/ml poly(I:C). Supernatants were collected after 8 and 24 h; IL-6 (K) and IFN-b (I) were measured by ELISA. Data
are the mean (6 SEM) of at least three independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001, unpaired Student t test.
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naling (Fig. 1D–F) (22, 23). We found that knockdown of IRAK1
led to a significant increase in the activation of the IFN-b reporter
relative to control siRNA (lamin A/C)-transfected cells (Fig. 1D),
which was comparable to A20 knockdown cells. To our knowl-
edge, increased activation of the IFN-b–PRDII reporter and the
p65 reporter in IRAK1-knockdown cells (Fig. 1F, Supplemental
Fig. 1B) provides the first evidence that endogenous IRAK1
may act as a negative regulator of the TLR3–NF-kB–signaling
pathway. Previous work implicated IRAK1 as a negative regu-
lator of TRIF-mediated activation of IRF-3 and IRF-7 (2). Our
work supports this previously published study, because IRAK1-
knockdown cells showed increased activation of the IFN-b–
PRDIII-I reporter (Fig. 1E) and both the IRF3 (Supplemental Fig.
1A) and IRF7 (data not shown) reporters compared with control
siRNA-treated cells following poly(I:C) stimulation. To address
the role of IRAK1 in TLR3 signaling in immune cells, IRAK12/2
BMDMs were stimulated with poly(I:C) in parallel with WT
BMDMs. IFN-b mRNA levels were assessed by quantitative real-
time PCR, and IFN-b protein levels were measured by ELISA.
IFN-b mRNA levels increased significantly in IRAK12/2 BMDMs
compared with WT BMDMs; significance was evident at the 2-h
time point (Supplemental Fig. 2A). Increased levels of IFN-b, as
assessed by ELISA, were detected in the IRAK12/2 macrophages
compared with WT macrophages at 8 and 24 post-poly(I:C)
stimulation (Fig. 1G). In contrast, and in line with recently pub-
lished work (24), no such increase in IFN-b levels was observed in
the IRAK12/2 macrophages compared with WT macrophages
following LPS stimulation (Fig. 1H). We used the IRAK1/4 in-
hibitor to assess the role of kinase activity of IRAK1 in the TLR3
pathway. WT BMDMs were pretreated with the IRAK1/4 inhib-
itor or the inhibitor diluent, DMSO, and the cells were stimulated
with poly(I:C) for specific periods of time. The IRAK1/4 inhibitor
enhanced IFN-b induction and type I IFN production in the
IRAK1/4 inhibitor–pretreated cells compared with the DMSO-
treated cells (Fig. 1I, Supplemental Fig. 2B). Because we ob-
served an IRAK1-mediated inhibition of the PRDII reporter (Fig.
1C, 1F), we next measured IL-6 levels by ELISA, because NF-kB
has a critical regulatory role in the transcriptional regulation of IL-
6. Increased levels of IL-6 (Fig. 1J) were measured by ELISA in
the IRAK12/2 macrophages relative to the WT macrophages at 8
and 24 h following poly(I:C) stimulation. The IRAK1/4 inhibitor
enhanced IL-6 levels at 8 and 24 h following poly(I:C) stimulation
(Fig. 1K). To address whether the findings in murine macrophages
are representative of human immune cells, we analyzed the ex-
pression levels of IFN-b mRNA by quantitative real-time PCR
and measured IL-6 by ELISA in the human microglial cell line
CH3ME using the IRAK1/4 inhibitor (Supplemental Fig. 2C, 2D).
Increased levels of IFN-b mRNA and IL-6 were found in IRAK1/4
inhibitor–pretreated, poly(I:C)-stimulated microglial cells com-
pared with DMSO-treated cells.
IRAK1 limits activation of the TLR3-activated NF-kB– and
IRF3-signaling pathways in macrophages
We next examined the activation status of IRF3 and p65. Our work
has shown a novel role for IRAK1 in NF-kB regulation and pre-
vious work showed a role in IRF3 regulation. IRAK12/2 and WT
BMDMs were stimulated with poly(I:C) for 0, 15, or 45 min or 1,
2, or 4 h, and the activation status of NF-kB and IRF3 was ex-
amined by Western blot analysis (Fig. 2A). We observed increased
phosphorylation of IRF3 (Ser396) and p65 (Ser536) in IRAK12/2
macrophages compared with WT macrophages. This increase was
evident after 45 min of poly(I:C) stimulation for both p65 and
IRF3. The kinases IKKa/b, TBK1, and IKKε have all been im-
plicated in p65 phosphorylation at serine residue 536, and TBK1
is the critical kinase involved in IRF3 activation (16, 17). A
marked increase in phosphorylation of IKKb (Ser177; upper band)
and TBK1 (Ser172) was observed in IRAK12/2 macrophages
compared with WT macrophages after 45 min of poly(I:C) stim-
ulation. Recent work by Cohen’s group (20) showed that the
noncanonical kinases TBK1 and IKKε are substrates of the ca-
nonical kinases IKKa/b, which suggests that the increased IKKb
activation observed in IRAK12/2 macrophages may contribute to
the increased phosphorylation of TBK1. We next decided to ex-
amine the signaling profile in WT BMDMs using the IRAK1/4
inhibitor (Fig. 2C). WT BMDMs were pretreated with the IRAK1/
4 inhibitor or the inhibitor diluent DMSO, and the cells were
stimulated with poly(I:C) for specific periods of time (0, 15, or 45
min or 1, 2, or 4 h). The IRAK1/4 inhibitor–treated cells exhibited
a similar activation profile as the IRAK12/2 BMDMs. IKKb and
TBK1 were hyperactivated following poly(I:C) stimulation in the
IRAK1/4 inhibitor–treated cells compared with DMSO-treated
cells (Fig. 2C). This work suggests that the kinase activity of
IRAK1 is required to limit the activation of IRF3 and NF-kB in
the TLR3-signaling pathway.
Impaired phosphorylation of IKK« and enhanced
phosphorylation of TBK1 in IRAK12/2 BMDMs following
poly(I:C) stimulation
A key event in the activation of the IKK-related kinases TBK1 and
IKKε is their phosphorylation at Ser172, which is located in the
activation loop of these kinases. Ectopic expression of TBK1 and
IKKε leads to their autoactivation. While probing the IRAK1-
mediated regulation of the TLR3 pathway, we found that phos-
phorylation at Ser172 was not detected for flag-tagged IKKε in
IRAK1-deficient HEK2931IA cells, whereas it could be clearly
seen in parental HEK293 cells (Fig. 3A). In contrast, immuno-
blotting showed comparable levels of phosphorylation at Ser172
for TBK1 in HEK293I1A cells and the parental HEK293 cells
(Fig. 3A). We found that overexpression of kinase-inactive IRAK1
in the HEK2931IA cells did not lead to the phosphorylation of
IKKε at Ser172 (Fig. 3A). This work suggests that the kinase ac-
tivity of IRAK1 is required for the activation of IKKε. IRAK1 and
IKKε interacted in unstimulated macrophages, as well as fol-
lowing ligand stimulation, as assessed by endogenous immuno-
precipitations (Fig. 3B). Given the findings in HEK2931IA cells
and because the p-TBK1 Ser172 Ab used in Western blots cross-
reacts with p-IKKε, we sought to define the activation status of
TBK1 and IKKε, separately, in IRAK12/2 BMDMs. Endogenous
TBK1 and IKKε were immunoprecipitated from IRAK12/2
BMDMs [after 0 and 1 h of poly(I:C) stimulation], and the acti-
vation status of the noncanonical kinases was assessed by Western
blot analysis using the p-IKKε/TBK1 (Ser172) Ab. We found im-
paired phosphorylation of IKKε in both unstimulated cells and
following poly(I:C) stimulation in IRAK12/2 macrophages (Fig.
3C). Interestingly, the opposite profile was observed for TBK1
in IRAK12/2 macrophages (Fig. 3D), showing increased phos-
phorylation of TBK1 in both unstimulated cells and following
poly(I:C) stimulation. We next sought to address whether the ki-
nase activity of IRAK1 is involved in mediating the activation of
IKKε. WT BMDMs were pretreated with the IRAK1/4 inhibitor or
DMSO and then left untreated or stimulated with poly(I:C) for 45
min, 1 h, or 2 h. Endogenous IKKε was immunoprecipitated from
cell lysates, and the phosphorylation of Ser172 was analyzed by
immunoblotting. Use of the IRAK1/4 inhibitor led to reduced
phosphorylation of IKKε in both unstimulated cells and following
poly(I:C) stimulation (Fig. 3E). To our knowledge, this is the first
study to implicate IRAK1 in the activation of IKKε. At the same
time, this study showed that IRAK1 limits the activation of TBK1.
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IKK« limits activation of the TLR3–NF-kB– and
IRF3-signaling pathways similarly to IRAK1
Given that IRAK1 is required for the activation of IKKε, we next
investigated the functional role of IKKε in the TLR3-signaling
pathway. Surprisingly, poly(I:C)-stimulated IKKε2/2 BMDMs
resulted in enhanced induction of IFN-b mRNA, as assessed by
quantitative real-time PCR, and increased production of IFN-b
protein compared with WT BMDMs (Fig. 4A, Supplemental Fig.
3A). In contrast, no significant difference in IFN-b levels was
observed in IKKε2/2 BMDMs compared with WT BMDMs fol-
lowing LPS stimulation (Fig. 4B). We performed similar experi-
ments in the TBK1-deficient BMDMs (TBK12/2 TNFR2/2
FIGURE 2. Increased activation of IKKb and TBK1 in IRAK12/2 macrophages and in cells treated with the IRAK1/4 inhibitor. (A) WT or IRAK12/2
BMDMs were stimulated with poly(I:C) and harvested at the indicated times (0–4 h). Cell lysates were subjected to Western blot analysis. The membranes
were probed with the indicated Abs. Similar results were obtained in three independent experiments. (B) Relative ratio of phospho/total p65 and IRF3 in
WT and IRAK12/2 BMDMs at 45 min following poly(I:C) stimulation, as determined by densitometric analysis of three independent experiments. (C)
IRAK1/4 inhibitor– or DMSO-pretreated WT BMDMs were stimulated with poly(I:C) and harvested at the indicated times (0–4 h). Cell lysates were
resolved by SDS-PAGE and subjected to Western blot using the indicated Abs. Similar results were obtained in three independent experiments. (D) Relative
ratio of phospho/total p65 and IRF3 in WT BMDMs treated with DMSO or the IRAK1/4 inhibitor at 45 min following poly(I:C) stimulation, as determined
by densitometric analysis of three independent experiments.
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BMDMs) and the corresponding control cell line (TBK1+/+
TNFR2/2 BMDMs). We found that TBK1 is critical for IFN-b
production, because reduced IFN-b mRNA and cytokine levels were
observed following poly(I:C) stimulation, in line with published
work (25, 26) (Fig. 4C, Supplemental Fig. 3B). Poly(I:C) stimulation
of IKKε2/2 BMDMs also resulted in enhanced IL-6 production
compared with WT BMDMs (Fig. 4D). Interestingly, we found re-
duced IL-6 production in the TBK12/2 macrophages at the earlier
time point of 8 h, whereas no significant difference was observed
at 24 h (Fig. 4E). These data suggest that TBK1 has a positive role
in the TLR3–NF-kB–signaling pathway. We next examined the
phosphorylation/activation status of p65, IRF3, IKKa/b, and TBK1
and found enhanced phosphorylation of p65 and IRF3, together with
enhanced phosphorylation of their upstream kinases IKKb and
TBK1, in the IKKε2/2 BMDMs compared with WT macrophages
(Fig. 4F). In agreement with our data on IL-6, TBK1-deficient
BMDMs showed reduced phosphorylation of p65 compared with
matching BMDMs (Fig. 4F). This work highlights a novel positive
role for TBK1 in TLR3–NF-kB signaling and adds to the increasing
evidence for the divergent roles of these two kinases, TBK1 and
IKKε. The cytokine and immune-signaling profile found in IKKε2/2
BMDMs mirrors that of IRAK12/2 BMDMs, providing further
evidence of a tightly linked TLR3-IRAK1/IKKε–signaling axis.
IRAK1 and IKK« are involved in limiting the activation of
TAK1 in the TLR3-activated NF-kB pathway
Activation of MAPKs plays pivotal roles in the expression of
various cytokines, including TNF-a, IL-8, IL-6, and IL-12 (27).
Furthermore, JNK was shown to be involved in the phosphory-
lation of IRF3 (Ser173), acting as a positive regulator of IRF3
activation (28). Therefore, we addressed whether IRAK1 and
IKKε had a functional role in MAPK activation downstream of
TLR3, as assessed by Western blot analysis (Fig. 5A, 5B). Inter-
estingly, IRAK1- and IKKε-deficient BMDMs showed enhanced
phosphorylation of the MAPKs JNK and p38 compared with
WT cells (Fig. 5A, 5B). We next assessed whether the kinase
activity of IRAK1 is involved in the modulation of MAPK acti-
vation. We observed enhanced activation of JNK and p38 in cells
treated with the IRAK1/4 inhibitor (Fig. 5C). The use of the
IRAK1/4 inhibitor does not exclude the possibility that IRAK4
has a regulatory role in TLR3-MAPK activation. We next exam-
ined the activation status of TAK1, because it has a critical role in
NF-kB activation and a regulatory role in JNK activation in the
TLR3-signaling pathway (7). First, to assess more comprehen-
sively the role of TAK1 in TLR3-mediated MAPK and NF-kB
activation, BMDMs were treated for 1 h with DMSO or the TAK1
inhibitor (5Z)-7-oxozeaenol and then stimulated with poly(I:C) for
FIGURE 3. IRAK1 is involved in the activation of IKKε. (A) WT and IRAK1-deficient (I1A) HEK293 cells were transfected with EV pcDNA3.1 or
expression constructs for flag-tagged IKKε or flag-tagged TBK1. IRAK1-deficient (I1A) HEK293 cells were reconstituted with kinase inactive IRAK1
(IRAK1 KD; 2 mg) together with EV pcDNA3.1 or flag-tagged IKKε or flag-tagged TBK1 expression constructs. After 24 h, cells were lysed, and whole-
cell lysates were analyzed by Western blotting (WB) with anti–phospho-S172, anti-flag, anti-IRAK1, and anti–b-actin Abs. Similar results were obtained in
three independent experiments. (B) WT BMDMs were treated with poly(I:C) for the indicated times and then harvested. Cell lysates were subjected to
immunoprecipitation (IP) with the anti-IRAK1 Ab or, as a control, rabbit IgG. The IPs were run on SDS-PAGE and probed with an anti-IKKε Ab, as well as
anti-IRAK1 as a control for equal IP. The expression levels of endogenous IKKε and IRAK1 were also examined in whole-cell lysates (WCL). Similar
results were obtained in two independent experiments. (C and D) WT or IRAK12/2 BMDMs were treated for 1 h with 50 mg/ml poly(I:C) and then
harvested. Lysates were immunoprecipitated with anti-IKKε (C) or anti-TBK1 (D) and subjected to SDS-PAGE and Western blot for p-S172 TBK1/IKKε.
Whole cell lysates were also probed for anti-IKKε (C) and TBK1 (D), as indicated. Similar results were obtained in three independent experiments. (E) WT
BMDMs were pretreated for 1 h with 1 mM IRAK1/4 inhibitor or an equal amount of DMSO and then stimulated with 50 mg/ml poly(I:C) for 45 min or 1
or 2 h. Cells were lysed and subjected to IP using anti-IKKε Ab. The samples were subjected to SDS-PAGE and Western blot and probed for anti-p-Ser172
TBK1/IKKε and total IKKε, as indicated. Whole-cell lysates were probed for IKKε. Similar results were obtained in four independent experiments.
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FIGURE 4. IKKε limits activation of the TLR3–NF-kB and -IRF3–signaling pathways similarly to IRAK1. WT and IKKε2/2 BMDMs (A, B, D) or
TBK1+/+ TNFR12/2 BMDMs and TBK12/2 TNFR12/2 BMDMs (C, E) were stimulated with 50 mg/ml poly (I:C) (A, D, C, E) or LPS (1 mg/ml) (B) for the
indicated times; IFN-b and IL-6 were measured by ELISA. Data are the mean 6 SEM of at least three experiments. (F) WT and IKKε2/2 BMDMs or
TBK1+/+ TNFR12/2 BMDMs and TBK12/2 TNFR12/2 BMDMs were stimulated with 50 mg/ml poly(I:C) and harvested at the indicated times (0–4 h).
Whole-cell lysates were resolved by SDS-PAGE and subjected to Western blot using the indicated Abs. Similar results were obtained in at least three
independent experiments. (G) Scheme showing the role of TBK1 and IKKε in the TLR3–NF-kB pathway. (H) Relative ratio of phospho/total p65 and IRF3
in WT and IKKε2/2 BMDMs at 45 min following poly(I:C) stimulation, as determined by densitometric analysis of three independent experiments. (I)
Relative ratio of phospho/total p65 in TBK1+/+ TNFR12/2 BMDMs and TBK12/2 TNFR12/2 BMDMs after 45 min of poly(I:C) treatment, as determined
from densitometric analysis of three independent experiments. **p , 0.01, ***p , 0.001, unpaired Student t test.
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0 or 45 min or 1 or 2 h (Fig. 5D). Reduced phosphorylation of
JNK and p38 MAPK was evident in inhibitor-treated cells and was
notably more pronounced for JNK. A significant reduction in the
phosphorylation of p65 (Ser536) was also observed in cells pre-
treated with the TAK1 inhibitor compared with DMSO-treated
cells. A slight reduction in the phosphorylation of TBK1 was
also observed. Altogether, these data confirm a positive role for
TAK1 in TLR3-induced JNK and p38 activation, as well as p65
activation. A marked increase in the activation status of TAK1 was
detected in both IRAK12/2 and IKKε2/2 macrophages following
poly(I:C) stimulation [as early as 30 min following poly(I:C)
stimulation] compared with WT macrophages (Fig. 5E). This in-
crease in TAK1 activation could explain the observed increase in
both JNK and p38 activation in the IRAK12/2 and IKKε2/2
macrophages. To address whether the kinase activity of IRAK1 is
involved in limiting the activation of TAK1 in TLR3 signaling, we
again used the IRAK1/4 inhibitor. We found increased activation of
TAK1 in BMDMs that were pretreated with IRAK1/4 inhibitor and
stimulated with poly(I:C) (Fig. 5F). To our knowledge, this is the
first study to implicate IRAK1 and IKKε in the signaling events
upstream or at the level of TAK1 in the TLR3-signaling cascade.
IRAK1 and IKK« are involved in activation of ERK1/2
downstream of TLR3
While examining the role of IRAK1 and IKKε in MAPK activa-
tion, we found that the activation of ERK1/2 was abolished fol-
lowing poly(I:C) stimulation in IRAK12/2 and IKKε2/2 BMDMs
(Fig. 6A, 6B). In cells treated with the IRAK1/4 inhibitor, ERK1/2
activation was also impaired following poly(I:C) stimulation (Fig.
6C). To investigate whether the kinase activity of IKKε is also
required for the activation of ERK1/2, we treated WT BMDMs with
a TBK1/IKKε inhibitor (MRT67307) for 1 h prior to poly(I:C)
FIGURE 5. IRAK1 and IKKε negatively regulate the TAK1-JNK/p38 MAPK–signaling axis. WT and IRAK12/2 BMDMs (A) or WT and IKKε2/2
BMDMs (B) were not treated or were stimulated with 50 mg/ml poly(I:C) and analyzed by Western blot using the indicated Abs. Representative data of three
independent experiments are shown. (C) WT BMDMs were pretreated for 1 h with 1 mM IRAK1/4 inhibitor or an equal amount of DMSO and then
stimulated with poly(I:C), as indicated. The phosphorylation of the MAPKs was monitored by Western blotting. (D) WT BMDMs were treated for 1 h with
1 mM (5Z)-7-oxozeaenol prior to stimulation with 50 mg/ml poly(I:C) for the indicated times. Whole-cell lysates were immunoblotted with the indicated Abs.
Representative data of three independent experiments are shown. (E) WT, IRAK12/2, and IKKε2/2 BMDMs were treated in parallel with 50 mg/ml poly(I:C)
for the indicated times. Whole-cell lysates were subjected to SDS-PAGE and Western blot analysis using p-TAK1 and total TAK1 Abs. Representative data of
three independent experiments are shown. (F) WT BMDMs were treated for 1 h with 1 mM IRAK1/4 inhibitor or an equal amount of DMSO and then
stimulated with 50 mg/ml poly(I:C) for the indicated times. Cell lysates were subjected to immunoblotting with phospho- and total-TAK1 Abs. Representative
data of three independent experiments are shown. (G) Scheme showing the role of IRAK1 and IKKε in the regulation of the MAPK pathway.
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stimulation. The phosphorylation of ERK1/2 was severely impaired
in the presence of MRT67307, indicating that the kinase activity of
TBK1 and/or IKKε is involved in the activation of ERK1/2 (Fig. 6D).
The activation status of ERK1/2 was assessed in TBK1-deficient
BMDMs (TBK12/2 TNFR2/2 BMDMs) compared with the corre-
sponding control cells (TBK1+/+ TNFR2/2 BMDMs). We found that
ERK1/2 was activated following poly(I:C) stimulation in TBK1-
deficient cells (Fig. 6E), indicating that the effect observed with
MRT67307 resulted from the inhibition of IKKε. Taken together,
these findings indicate that IRAK1 and IKKε are novel positive reg-
ulators of ERK1/2 activation in the TLR3-signaling pathway.
The TAK1 inhibitor (5Z)-7-oxozeaenol reduces IFN-b mRNA
levels in IRAK12/2 and IKK«2/2 BMDMs following poly(I:C)
stimulation
To gain further insight into the mechanism by which IRAK1 and
IKKε modulate IFN-b production downstream of TLR3, WT,
IRAK12/2, and IKKε2/2 BMDMs were treated for 1 h with
DMSO or the TAK1 inhibitor (5Z)-7-oxozeaenol and then stim-
ulated with poly(I:C) for 2 h (Fig. 7A, 7B). IFN-b mRNA levels
were measured by quantitative RT-PCR in the WT, IRAK12/2,
and IKKε2/2 BMDMs (Fig. 7A, 7B). Inhibition of TAK1 led to
a slight reduction in the levels of IFN-b following poly(I:C)
treatment in WT BMDMs, although this difference was not sig-
nificant (Fig. 7A). This is in line with recent data indicating that
NF-kB has a minor role in IFN-b induction following viral in-
fection (18). Increased IFN-b mRNAwas observed in the DMSO-
pretreated, poly(I:C)-stimulated IRAK12/2 and IKKε2/2
BMDMs compared with the DMSO-treated WT cells, as seen
previously (Fig. 7A, 7B, Supplemental Figs. 2A, 3A). Pretreat-
ment of the IRAK12/2 and IKKε2/2 BMDMs with the TAK1
FIGURE 6. IRAK1 and IKKε are involved in the activation of ERK1/2
downstream of TLR3. WT and IRAK12/2 BMDMs (A) or WT and IKKε2/2
BMDMs (B) were not treated or were stimulated with 50 mg/ml poly(I:C)
and analyzed by Western blot using the indicated Abs. Representative data of
three independent experiments are shown. (C) WT BMDMs were treated for
1 h with 1 mM IRAK1/4 inhibitor or an equal amount of DMSO and then
stimulated with poly(I:C), as indicated. The phosphorylation of ERK1/2 was
assessed by Western blotting. (D) WT BMDMs were treated for 1 h with 2
mM MRT67307 or an equal amount of DMSO and then stimulated with 50
mg/ml poly(I:C) for the indicated times. Cell extracts were immunoblotted
with phospho- and total-ERK1/2, as indicated. (E) TBK1+/+ TNFR12/2
BMDMs and TBK12/2 TNFR12/2 BMDMs were stimulated with 50 mg/ml
poly(I:C) for the indicated times. Whole-cell lysates were analyzed by im-
munoblotting with anti–phospho- and total-ERK1/2. Representative data
from three independent experiments are shown.
FIGURE 7. The TAK1 inhibitor, (5Z)-7-oxozeaenol, significantly reduces
the elevated IFN-b responses in IRAK12/2 and IKKε2/2 BMDMs.
IRAK12/2 BMDMs (A) or IKKε2/2 BMDMs (B) were treated for 1 h with
1 mM (5Z)-7-oxozeaenol or DMSO and then stimulated with 50 mg/ml poly
(I:C) for 2 h. WT BMDMs were treated in parallel with DMSO and then
stimulated with poly(I:C) for 2 h. The transcriptional level of Ifnb was
determined by real-time PCR and normalized against GAPDH mRNA
(mean6 SEM; n = 3). (C) IRAK12/2 BMDMs and IKKε2/2 BMDMs were
treated for 1 h with DMSO or 1 mM (5Z)-7-oxozeaenol and then stimulated
with 50 mg/ml poly(I:C) for 45 min. WT BMDMs were treated with DMSO
and stimulated with poly(I:C) for 45 min. Whole-cell extracts were sub-
jected to Western blot analysis with the indicated Abs. Representative data
of three independent experiments are shown. *p , 0.05, **p , 0.01,
***p , 0.001, unpaired Student t test.
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inhibitor led to a significant reduction in IFN-b induction fol-
lowing poly(I:C) stimulation compared with DMSO-treated
IRAK12/2 and IKKε2/2 BMDMs (Fig. 7A, 7B). In Western
blots, reduced phosphorylation of p65 and IRF3 was detected in
IRAK12/2 and IKKε2/2 BMDMs that were pretreated with TAK1
inhibitor versus DMSO. This indicates that hyperactivation of
TAK1 is largely responsible for the increased level of TBK1 ac-
tivation and, consequently, IRF3 activation in IRAK12/2 and
IKKε2/2 BMDMs. Interestingly, the level of activation of TBK1
and IRF3 in the IRAK12/2 TAK1 inhibitor–treated macrophages
remained higher compared with WT DMSO-treated macrophages.
The same was not true for the IKKε2/2 TAK1 inhibitor–pretreated
BMDMs. Preliminary work suggests that IRAK1 inhibits the
TLR3-activated IRF3 and IRF7–signaling axis; hence, IRAK1
acts at multiple levels to control the magnitude of the type I IFN
response downstream of TLR3.
IRAK1 does not inhibit the TLR3–NF-kB–signaling axis in the
absence of IKK«
Given our findings that IRAK1 and IKKε interact and that both
limit activation of the TLR3–NF-kB–signaling pathway, we in-
vestigated whether modulation of this pathway by IRAK1 is IKKε
dependent. First, we silenced the expression of IKKε in TLR3-
HEK293 cells using two independent siRNA oligonucleotides. In
agreement with our data on murine macrophages, knockdown of
IKKε led to a significant increase in both the activation of the IFN-
b promoter and PRDII reporters relative to control siRNA (lamin
A/C)-transfected cells (Fig. 8A, 8B). Increased activation of the
IFN-b–PRDII reporter in IKKε-knockdown cells (Fig. 8B) pro-
vided evidence that endogenous IKKε limits activation of the
TLR3–NF-kB–signaling pathway in human cells. Both siRNA
oligonucleotides gave comparable results and reduced the ex-
pression of IKKε by ∼70 and ∼90%, as assessed by Western blot
analysis (Fig. 8C, 8D). Next, we addressed whether IRAK1 acts
through IKKε in limiting activation of the TLR3–NF-kB–signal-
ing pathway. To address this central question, we transfected
IRAK1 or EV expression constructs 48 h following the siRNA
transfection against IKKε or lamin A/C, stimulated the cells with
poly(I:C), and compared the results from the control siRNAversus
the IKKε siRNA reporters. Ectopic expression of IRAK1 in IKKε-
knockdown cells inhibited poly(I:C)-stimulated activation of the
IFN-b reporter (Fig. 8A). Examining the IFN-b–PRDII luciferase
reporter gave us mechanistic insight into the IRAK1–IKKε sig-
naling relationship. IRAK1 failed to inhibit poly(I:C)-stimulated
activation of the IFN-b–PRDII luciferase reporter in the absence
of IKKε. This result indicates that IRAK1 requires IKKε to me-
diate the negative regulation of the TLR3–NF-kB–signaling axis
(Fig. 8B). IRAK1 inhibits activation of the IFN-b luciferase re-
porter following poly(I:C) stimulation in IKKε-silenced cells. This
suggests that IRAK1 can also act independently of IKKε in the
regulation of TLR3-mediated IRF3 and/or -7 activation. We
present a summary of our research findings in Fig. 9.
Discussion
IRAK1 was previously reported to inhibit TRIF- and RIG-I–me-
diated IFN-b induction; however, limited mechanistic insight into
this inhibition was uncovered (2). That study suggested that
IRAK1 inhibits the activation of IRF3 and IRF7 (2). Contrary to
this work, a later study reported that IRAK1 is required for IFN-b
induction in the RIG-I–signaling pathway in murine macrophages
(29).
Our work shows that IRAK-1 limits the activation of TAK1 in
the TLR3-signaling pathway. We found increased TAK1, IKKb,
and TBK1 activation in IRAK-1–deficient macrophages following
poly(I:C) stimulation. Increased IKKb and TBK1 activity most
likely contributes to the increased IL-6 and IFN-b cytokine levels
following TLR3 stimulation in IRAK12/2 macrophages compared
with WT macrophages. The increased IKKb activation may
contribute to the observed increase in TBK1 activity and, conse-
quently, the increased IRF3 activation. Our understanding of the
FIGURE 8. IRAK1 inhibits the TLR3–
NF-kB pathway through an IKKε-depen-
dent mechanism. (A and B) IKKε was si-
lenced in TLR3 HEK293 cells using two
siRNAs (IKKε siRNA 1 and IKKε siRNA
2) at a final concentration of 30 nM.
siRNA and lamin A/C (30 nM) were used
as control. After 48 h, the cells were
transfected, with the IFN-b promoter (A)
and PRDII (B) reporter constructs as pre-
viously described, and a plasmid encoding
for IRAK1 (100 ng) or EV (100 ng), as
shown. After 24 h, the cells were stimu-
lated with poly(I:C) for 6 h, and the re-
porter gene activities were normalized by
Renilla luciferase expression. Data are
presented as fold stimulation of luciferase
expression relative to unstimulated cells.
Data are shown as mean 6 SEM (n = 4).
(C) The knockdown of IKKε was con-
firmed by Western blot analysis, using
siRNA against lamin A/C as a control. (D)
Plot shows reduced densitometry of IKKε
protein levels by IKKε siRNA 1 and IKKε
siRNA 2 transfection compared with lamin
A/C siRNA (n = 4/group). Values were
normalized to b-actin. *p , 0.05, **p ,
0.01, ***p , 0.001, unpaired Student t
test.
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IKKb–TBK1 link comes from work showing that IKKa and
IKKb directly phosphorylate TBK1 and IKKε at serine 172 in the
activation loop (20). In TLR3 signaling, a second pathway, not yet
defined, leads to the autoactivation of TBK1 and IKKε (20).
To assess whether the kinase activity of IRAK1 is critical in
mediating this negative regulation of the TLR3-signaling pathway,
we used an IRAK1/4 dual-specific inhibitor, because an IRAK1-
specific inhibitor is not available commercially. The use of the
IRAK1/4 inhibitor on WT macrophages reproduced our findings
with the IRAK1-deficient macrophages showing increased IL-6
and IFN-b production following TLR3 stimulation. Previous
work had already addressed the role of IRAK4 and its kinase
activity in TLR3 signaling. Comparable levels of IL-6, TNF-a,
and IFN-a were detected in IRAK42/2 and WT macrophages
following TLR3 stimulation (30). Furthermore, inactivation of the
kinase activity of IRAK4 failed to modulate the TLR3–IL-6 re-
sponse (30, 31). Therefore, our data suggest that the kinase ac-
tivity of IRAK1, rather than IRAK4, is required to mediate this
negative regulation of the TLR3–NF-kB pathway. Recently, dif-
ferences in the requirements for IRAK1/4 kinase activity in IL-1R
signaling have emerged between human and mouse immune cells,
indicating that the kinase activity is dispensable in IL-1R signal-
ing in human cells (32). We found that blocking the kinase activity
of IRAK1 and IRAK4 through the use of the dual IRAK1/4 kinase
inhibitor limits the activation of the TLR3 pathway in human
cells, because increased IL-6 and IFN-b levels were found in
human microglial cells, which were pretreated with the IRAK1/4
inhibitor, following poly(I:C) stimulation.
Emerging data indicate divergent functional roles for the kinases
TBK1 and IKKε, together with differences in their cellular lo-
calization and activation mechanisms (17, 33–36). Previous work
used a dual-specific inhibitor of TBK1/IKKε to determine that
the noncanonical kinases act in a negative-feedback loop to
limit the activity of the canonical IKKs (35). Our work showed
that TBK1 is involved in the positive regulation of NF-kB down-
stream of TLR3. In contrast, we report that IKKε is not involved
in the positive regulation of this same pathway, highlighting their
differences at the functional level in the TLR3 pathway. Because
TBK12/2 mice are embryonic lethal, investigators have used em-
bryonic fibroblasts, siRNA targeting TBK1, TNFR12/2 TBK12/2
double-knockout mice, and, more recently, TBK1-mutant mice
that encode a mutant TBK1 protein lacking catalytic activity.
Previous studies established a positive role for TBK1 in TNF- and
IL-1–induced transcriptional activity of NF-kB in embryonic
fibroblasts (37). In contrast to our findings of reduced IL-6 pro-
duction following poly(I:C) stimulation, other investigators re-
ported no difference in mouse embryonic fibroblasts using siRNA
against TBK1 or in macrophages from the TBK1-mutant mice
(38, 39). Perhaps the conflicting results arise from functional
differences for TBK1 that are dependent on cell type, or it may be
that the scaffold function, rather than the catalytic activity of
TBK1, is important for TLR3-induced NF-kB activation. We show
that IKKε is involved in the negative-feedback loop of the TLR3–
NF-kB pathway. No significant difference in poly(I:C)-induced
IL-6 production was detected in BMDMs from TBK1-mutant
mice (38), which provides further support that IKKε is the key
kinase negatively regulating the TLR3–NF-kB axis. Future work
will identify whether IKKε and/or TBK1 is the kinase limiting
IKK activity downstream of TLR2, -4, and -9. IKKε was reported
to limit type I IFN production in the RIG-I–signaling pathway,
acting at the level of MAVS and leading to the dissociation of
TRAF3 from MAVS (34). The kinase activity of IKKε was found
not to be required for the disruption of the RIG-I/MAVS/TRAF-3
interactome (34). Our work advances knowledge on TLR3 sig-
naling, implicating IKKε as a novel regulator of the signaling
pathways regulating the production of IFN-b and proinflammatory
cytokines.
Impaired activation of IKKε in IRAK1-deficient macrophages
following poly(I:C) stimulation provides, to our knowledge, the
first evidence that IRAK1 is involved in the activation of IKKε.
We also demonstrated that IKKε activation is inhibited using an
IRAK1/4 kinase inhibitor. The availability of specific IRAK1 and
IRAK4 kinase inhibitors will more fully address the role of
IRAK1 and/or IRAK4 in the activation of IKKε. TANK-deficient
cells also show impaired activation of IKKε, together with re-
duced TBK1 activity following TLR-2, -4, and -9 signaling (35).
TANK-deficient macrophages show increased NF-kB activation in
response to TLR ligands. The interaction between the IKK-related
kinases and the canonical IKKs is reduced in TANK-deficient
cells, preventing the IKK-related kinases from negatively regu-
lating the canonical IKKs (35). It would be interesting to assess
the interaction between IKKε and IKKb in IRAK1-deficient
macrophages. Our siRNA work suggests that IRAK1 acts
through IKKε to mediate its negative-regulatory effect on the
TLR3–NF-kB–signaling pathway. Importantly, we identified
IKKε as the key signaling molecule regulating the TLR3-
stimulated inflammatory cytokine response, limiting the activa-
tion of NF-kB. The identity of the target(s) of IKKε will be the
focus of future work in this field. We show increased TAK1 ac-
tivity in IKKε-deficient macrophages following TLR3 stimulation.
Pharmacological inhibition of TAK1 in IRAK1- and IKKε-defi-
cient macrophages led to reduced IFN-b responses to poly(I:C),
comparable to WT macrophages. These findings suggest that
IKKε is targeting a signaling molecule upstream of the IKK
complex. Interestingly, TANK2/2 macrophages, which have im-
paired activation of IKKε, show enhanced E3 ligase activity of
TRAF6 following TLR7 stimulation (40).
The importance of MAPKs in the regulation of cytokine pro-
duction prompted us to examine the activation status of JNK, p38,
and ERK following poly(I:C) stimulation in the IRAK1- and IKKε-
deficient macrophages. We detected increased activation of JNK
and p38 and impaired phosphorylation of ERK1/2 following
poly(I:C) stimulation in both the IRAK-1– and IKKε-deficient
BMDMs. The increased activation of JNK and p38 results from
increased TAK1 activity. We found that the kinase activity of
FIGURE 9. Schematic representation of the TLR3-signaling pathway
building on our findings presented in this article. Following TLR3 stim-
ulation, the NF-kB– and IRF3/7-signaling pathways become activated,
which then lead to the production of proinflammatory cytokines and IFN-
b. Mechanisms are in place to prevent hyperactivation of these signaling
pathways. Our work shows that IRAK1 activates IKKε following TLR3
stimulation, which then limits activation of the TAK1–IKKb–NF-kB–
signaling axis. IRAK1 also negatively regulates the TLR3–IRF3/7–con-
trolled IFN-b response in separate pathways, but the mechanisms have yet
to be uncovered.
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IKKε is required for ERK1/2 activation. To our knowledge, this is
the first report showing that IRAK1 and IKKε are required for
ERK1/2 activation downstream of TLR3. Future work will address
whether the kinase activity of IRAK1 is required for ERK1/2
activation and examine how IRAK1 and IKKε facilitate ERK1/2
activation downstream of TLR3.
This work has provided mechanistic understanding of IRAK1’s
negative regulation of the TLR3–IFN-b and proinflammatory cyto-
kine response. We show a novel role for IRAK1 and IKKε in reg-
ulating the intensity of the TLR3–NF-kB–signaling pathway,
uncovering an IRAK1–IKKε–TAK1–directed regulatory mecha-
nism. Importantly, IRAK1 has emerged as a novel positive up-
stream regulator of IKKε. Finally, we show that IRAK1 regulates
the intensity of IFN-b production acting at multiple levels, which
highlights the complexity of signaling regulation in the TLR3
pathway.
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